1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Bristol's CheckMate 067 Revives Debate On Rationing Yervoy/Opdivo Combo

 
• By Emily Hayes

Yervoy/Opdivo combo proves significant survival benefit over Yervoy alone in Phase III frontline melanoma study, but is on par with Opdivo alone in patients with higher PD-L1 expression.

T-cells attacking cancer_1200x675

Survival data for Bristol-Myers Squibb Co.'s Yervoy/Opdivo combination in the CheckMate 067 study in frontline melanoma reinforce the regimen's potency, but also revive a debate about whether the regimen should be reserved for select subsets of patients, with others getting enough benefit from Opdivo alone or other treatment options.

The combination of Yervoy (ipilimumab), a CTLA-4 inhibitor, and Opdivo (nivolumab), a PD-1 inhibitor, received accelerated approval from FDA in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

More from Therapy Areas

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.